查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095683

胃癌治療市場－2026-2032年全球市場預測

Stomach Cancer Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胃癌治療市場將成長至 127.9 億美元，複合年成長率為 11.16%。

主要市場統計數據
基準年 2025 61億美元
預計年份：2026年 67.1億美元
預測年份 2032 127.9億美元
複合年成長率 (%) 11.16%

隨著醫療系統應對胃癌和胃食道交界處癌持續帶來的沉重負擔，胃癌治療正在經歷一場至關重要的臨床和營運變革。全球癌症監測數據顯示，胃癌仍是全球癌症發生率和癌症相關死亡率的主要原因之一，其預後很大程度上取決於診斷時的疾病分期和能否獲得專科治療。治療路徑越來越傾向於多學科腫瘤治療方案，該方案結合了手術、化療、放射線治療、分子標靶護。來自領先腫瘤機構的檢驗臨床指南強調基於生物標記的決策，包括HER2狀態、錯配修復（MSR）或微衛星不穩定性（MSI）狀態、PD-L1表達以及影響治療選擇的新興分子突變。同時，早期發現、手術全期最佳化、症狀管理和倖存者照護在改善患者預後方面發揮核心作用。胃癌的整體情況受多種因素影響，包括確診時的疾病分期、腫瘤的位置和組織學類型、幽門螺旋桿菌感染的風險模式、患者的身體狀況、診斷的可及性以及專科外科和全身治療服務的可用性。隨著相關人員對更有效、更公平的癌症治療的需求日益成長，胃癌治療體係正朝著精準腫瘤學、整合診斷、循證治療方案和以患者為中心的管理方向發展。

胃癌治療前景的變革性變化

目前，胃癌的治療正經歷著從標準化治療方案轉變為基於腫瘤生物學特徵和患者特定風險的個人化醫療。對於可切除的病變，手術全期化療和切除術仍然是治療的基礎，但全身性治療在進行性和轉移性胃癌中發揮核心作用。免疫療法改變了部分患者的治療流程，尤其是在免疫查核點抑制劑獲得生物標記證據和監管部門批准的情況下。標靶治療在HER2陽性病例和其他分子分型亞群中的重要性也日益凸顯，這強調了在診斷時進行高品質病理和分子檢測的必要性。微創手術和機器人輔助手術在具備必要技術和基礎設施的醫療機構中越來越受到臨床關注，而內視鏡切除術則用於治療符合既定標準的早期病變。支持性治療也日益系統化，越來越重視惡病質、貧血、吞嚥困難、疼痛、心理社會支持、治療相關毒性管理以及患者報告結局（PROs）。這些變化使胃癌治療模式更加複雜，同時也提升了臨床能力。治療價值的評估擴大從存活率、功能恢復、生活品質（QOL）和持續照護等方面進行。

人工智慧對胃癌治療的累積影響

人工智慧（AI）對胃癌治療的整個流程，尤其是影像診斷、觀察檢查、治療方案製定和臨床工作流程最佳化等方面，正產生日益顯著的影響。在內視鏡領域，人工智慧驅動的檢測工具正被研究和應用，以提高可疑胃部病變的識別準確率，支持早期診斷，並降低檢查者間的差異，尤其是在系統篩檢和內視鏡檢查量大的機構中。在放射學領域，機器學習模型正被用於評估其在腫瘤分期（利用影像特徵）、治療反應評估、淋巴結評估和復發風險預測方面的應用。數位病理學和計算分析可以輔助評估組織學模式和生物標記表達，但其臨床應用仍需外部檢驗、品管、互通性和監管。人工智慧也被用於整合電子健康記錄、分子譜、實驗室數據、影像結果和臨床記錄，以支持多學科腫瘤委員會的決策。這些措施的整體影響並非取代臨床專業知識，而是轉向更完善的數據驅動型決策支援、更快速的分診以及更一致的解讀。負責任的實施需要透明的演算法、代表性的訓練資料集、網路安全措施、臨床醫生監督，以及人工智慧工具能夠改善治療結果且不加劇差異的證據。

胃癌治療的關鍵區域見解

亞太地區胃癌負擔沉重，部分原因是東亞國家胃癌發生率高，以及一些醫療體系已建立起人群篩檢機制。日本和韓國長期以來開展胃癌篩檢項目，旨在促進早期發現，並對合格的早期病變進行內視鏡治療。同時，中國正在各大都會地區擴大癌症防治工作，並提升內視鏡系統、分子診斷和精準腫瘤學能力。在北美，雖然胃癌的發生率低於其他一些惡性腫瘤，但其治療高度依賴生物標記檢測、多學科診療、參與臨床試驗以及獲得先進的全身性治療。美國和加拿大強調實證指引、腫瘤支持服務和規範的轉診途徑。拉丁美洲在早期診斷、外科腫瘤體系、病理基礎設施、放射治療服務以及獲得新型全身治療方面存在差異，但巴西和墨西哥作為區域腫瘤服務中心，在腫瘤服務發展中發揮關鍵作用。在歐洲，基於指引的圍手術全期護理、統一的癌症治療路徑和分子診斷已被廣泛採用，但西歐、南歐、中歐和東歐的醫療體系在醫療費用報銷和專科醫生診療方面仍然存在差異。在中東，尤其是在海灣國家，隨著三級癌症中心、數位健康計畫和精準醫療計畫的擴展，癌症診療基礎設施正在加強，但資源匱乏地區的醫療服務取得仍然不均衡。非洲在及時診斷、內視鏡檢查、病理檢測能力、癌症醫療專業人員、放射治療以及治療費用可負擔性方面面臨最嚴峻的挑戰。加強醫療衛生體系建設、建立早期轉診途徑以及確保患者獲得必要的癌症治療對於改善胃癌的預後至關重要。

胃癌治療的關鍵區域見解

在東南亞國協，主要都市區擁有先進的癌症中心，但農村地區在篩檢、診斷性內視鏡檢查、病理檢查時間和生物標記檢測等方面仍然存在差距，導致胃癌治療格局存在地理差異。海灣合作理事會（GCC）國家的醫療衛生系統正在投資建設三級癌症中心、數位醫療基礎設施、專科癌症護理服務和國家癌症戰略，以支持更廣泛地採用多學科胃癌診療和在臨床適宜的情況下應用先進的全身治療。歐盟擁有協調一致的癌症政策框架、跨境研究合作、癌症登記基礎設施和已製定的臨床指南等優勢，但保險報銷、診斷能力、醫療服務提供者數量和轉診途徑的差異影響了治療的一致性。金磚國家整體呈現出廣泛而多樣的胃癌醫療衛生格局，中國和印度處理大量患者，巴西和俄羅斯正在建立專科癌症護理網路，而南非則面臨著醫療服務可及性方面的限制，這反映了更廣泛的區域差異。儘管七國集團（G7）國家普遍擁有完善的基礎設施，能夠提供先進的診斷、專科手術、免疫療法、標靶治療、支持性護理和臨床研究，但它們也面臨著人口老齡化、治療費用負擔、醫療專業人員短缺以及醫療服務公平獲取等挑戰。北約成員國的醫療體系與北美和歐洲許多高所得國家的醫療體系重疊。在這些地區，癌症防控準備、醫療物資供應的穩定性、數位化協調以及機構間合作有助於維持複雜癌症治療的連續性，但各國政策、保險報銷制度和服務機構的差異仍然影響著患者獲得醫療服務的機會。

各國對胃癌治療的重點見解

美國已建立起一套高度專業化的胃癌治療體系，其核心是多學科腫瘤團隊、生物標記檢測、臨床試驗、免疫療法、標靶治療以及為合格的患者提供複雜的外科上的照護。在加拿大，公共資助的癌症治療路徑、省級腫瘤計畫和基於指南的管理備受重視，但地區因素可能會影響患者獲得專業外科手術、內視鏡檢查和診斷服務的機會。墨西哥和巴西持續加強其癌症治療體系，主要都市區已具備先進的癌症治療服務，但診斷延遲、高昂的自付費用以及醫療服務取得方面的差異仍然是重要的障礙。在英國，已建立全國統一的標準化癌症治療路徑和基於實證醫學的治療啟動評估體系；而德國和法國則擁有強大的專業癌症治療網路、外科手術專家、診斷基礎設施和分子檢測能力。在義大利和西班牙，基於指南的圍手術全期護理、外科腫瘤學、放射腫瘤學和支持治療相結合，但不同地區的醫療服務取得和提供情況存在差異。俄羅斯正加強推動腫瘤學現代化，但區域間在診斷和治療上的差距仍影響著醫療保健。中國在全球胃癌診療中扮演著核心角色，這得益於其高疾病負擔、不斷擴展的內視鏡網路、日益精進的分子診斷能力以及活性化的臨床研究活動。在印度，大都會圈和醫療資源匱乏地區的腫瘤中心之間存在顯著差距，因此降低成本、早期診斷、病​​理能力以及專家診療服務成為重中之重。日本和韓國以其系統性篩檢、早期胃癌高檢出率、先進的內視鏡技術和完善的外科品管體係而聞名。在澳大利亞，以指引為基礎的多學科診療模式，輔以專業的癌症中心和臨床研究網路，並持續關注農村、偏遠地區和原住民社區的醫療服務可及性。

為行業領導者提供的實用建議

產業領導者應優先考慮整合胃癌診療模式，從診斷之初就協調胃腸病學、病理學、放射學、外科腫瘤學、內科腫瘤學、放射腫瘤學、營養學、復健和姑息治療等各學科。擴大經驗檢驗的生物標記檢測的覆蓋範圍對於合理應用免疫療法和分子標靶療法至關重要，尤其是在晚期胃癌和胃食道交界處癌的治療中。醫療機構應投資於提高內視鏡檢查品質、完善早期轉診途徑、標準化分期檢測和快速病理報告，以減少延誤並改善治療選擇。決策者應支持對臨床醫生進行培訓，內容涵蓋不斷更新的治療流程、毒性管理、分子診斷結果解讀、營養評估和以患者為中心的決策。應加強數位化基礎建設，以支持多學科腫瘤學會議、真實世界數據（REW）生成、治療依從性監測、生存期規劃和患者導航等工作。在發展中和資源匱乏地區，切實可行的優先事項包括擴大內視鏡檢查的覆蓋範圍、縮短病理結果報告時間、加強外科腫瘤學培訓、擴大放射治療的覆蓋範圍，以及建立經濟實惠的途徑獲得必要的全身治療。在所有情況下，領導者都應透過實證指標來衡量醫療品質，例如診斷時間、分期完整性、生物標記檢測率、治療完成率、術後結果、症狀控制、營養狀況以及患者自述的生活品質（QOL）。

調查方法

本執行摘要基於一項二手研究途徑，該方法利用了檢驗的臨床、監管、流行病學和公共衛生資訊來源。此調查方法強調來自同行評審的醫學文獻、腫瘤治療指南、癌症登記出版物、公共衛生機構資料、監管文件以及認證臨床機構的共識建議的證據。研究採用定性方法整合這些見解，以評估治療方法的演變、技術應用、區域可近性模式及其對臨床實踐的影響，而不使用市場規模、市場佔有率或預測數據。研究從疾病負擔、篩檢實踐、診斷能力、治療基礎設施、生物標記檢測的可及性、保險報銷環境、腫瘤人才儲備和醫療保健系統發展等方面評估了區域、群體和國家觀點。本分析優先考慮可重複性、資訊來源可靠性、臨床相關性以及與目前護理標準的一致性。由於胃癌治療發展迅速，因此解讀著重於實證主題，例如基於生物標記的治療、多學科診療、早期檢測、支持性治療和公平可及性，而非推測性的商業性預測。

結論

胃癌治療正朝著精準化、整合化和早期療育的方向發展。手術、化療、放療、放射線治療、標靶治療、內視鏡手術、營養支持和安寧療護等治療手段，擴大透過多學科協作模式進行整合，這些模式充分考慮了腫瘤分期、分子特徵、患者病情以及醫療系統能力。人工智慧、分子診斷和數位化醫療協調正在提升疾病檢測、個人化治療和療效監測的能力，但其價值取決於公平實施和臨床效益的證實。區域差異依然顯著，東亞地區的篩檢經驗、高所得國家獲得先進治療的機會以及許多中低收入國家基礎設施的不足，共同塑造了胃癌治療的現狀。最有效的策略是提高診斷準確性、擴大生物標記的可近性、減少治療延遲、建立實證治療方案、加強支持治療，並將患者的生活品質置於醫療服務的核心。隨著科學證據的不斷完善，胃癌治療領域的相關人員將透過整合創新、經濟性、營運準備和可衡量的臨床結果而蓬勃發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 胃癌治療市場：依治療類型分類

  • 化療
    • Fluoropyrimidines
    • 含鉑類藥物基
    • 基於紫杉烷類藥物
  • 免疫療法
  • 放射治療
    • 近距離放射治療
    • 外部輻射
  • 外科手術
    • 部分切除術
    • 全胃切除術
  • 標靶治療
  • 支持和輔助性治療

第8章 胃癌治療市場：依產品類型分類

  • 製藥
    • 細胞毒性抗癌藥物
      • Fluoropyrimidines藥物
      • 紫杉烷類藥物
      • Cisplatin
    • 生物製藥和單株抗體
    • 抗體藥物複合體
  • 醫療設備和設施
    • 外科產品
    • 內視鏡
    • 放射治療設備
    • 幫浦和導管

第9章 胃癌治療市場：依給藥途徑分類

  • 靜脈
  • 口服

第10章：胃癌治療市場：依階段分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第11章 胃癌治療市場：依適應症分類

  • 胃腺癌
  • 胃淋巴瘤
  • 胃食道交界處腺癌
  • 胃神經內分泌腫瘤

第12章：胃癌治療市場：依最終用戶分類

  • 居家照護
  • 醫院
  • 專科診所
  • 放射腫瘤中心

第13章：胃癌治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 胃癌治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 胃癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 胃癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeOne Medicines, Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Ipsen Pharma
  • Johnson & Johnson Services Inc.
  • LES LABORATOIRES SERVIER
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Prestige Biopharma
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceuticals Limited
  • Taiho Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-F927BA461E32

The Stomach Cancer Treatment Market is projected to grow by USD 12.79 billion at a CAGR of 11.16% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.10 billion
Estimated Year [2026] USD 6.71 billion
Forecast Year [2032] USD 12.79 billion
CAGR (%) 11.16%

Stomach cancer treatment is undergoing a decisive clinical and operational transition as healthcare systems respond to the continuing burden of gastric and gastroesophageal junction cancers. According to global cancer surveillance data, gastric cancer remains among the leading causes of cancer incidence and cancer-related mortality worldwide, with outcomes strongly influenced by stage at diagnosis and access to specialized care. Treatment pathways increasingly combine surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, endoscopic intervention, nutritional support, and palliative care within multidisciplinary oncology programs. Verified clinical guidance from major oncology bodies emphasizes biomarker-driven decision-making, including HER2 status, mismatch repair or microsatellite instability status, PD-L1 expression, and emerging molecular alterations that influence therapy selection. At the same time, earlier detection, perioperative optimization, symptom management, and survivorship care are becoming central to improving patient outcomes. The treatment landscape is shaped by disease stage at diagnosis, tumor location, histology, Helicobacter pylori-associated risk patterns, patient fitness, access to diagnostics, and availability of specialized surgical and systemic therapy services. As stakeholders seek more effective and equitable cancer care, the stomach cancer treatment ecosystem is advancing toward precision oncology, integrated diagnostics, evidence-based sequencing, and patient-centered management.

Transformative Shifts in the Stomach Cancer Treatment Landscape

The stomach cancer treatment landscape is being transformed by the movement from uniform treatment protocols toward individualized care based on tumor biology and patient-specific risk. Perioperative chemotherapy and gastrectomy with appropriate lymph node dissection remain foundational for resectable disease, while systemic therapy plays a central role in advanced and metastatic gastric cancer. Immunotherapy has altered treatment algorithms for selected patients, particularly where immune checkpoint inhibitors are supported by biomarker evidence and regulatory approval. Targeted therapy has also become increasingly important for HER2-positive disease and other molecularly defined subgroups, reinforcing the need for high-quality pathology and molecular testing at diagnosis. Minimally invasive and robotic-assisted surgical approaches are gaining clinical attention where expertise and infrastructure are available, while endoscopic resection is used for carefully selected early-stage lesions that meet established criteria. Supportive care is also becoming more structured, with greater attention to cachexia, anemia, dysphagia, pain, psychosocial support, treatment-related toxicity management, and patient-reported outcomes. These shifts are creating a more complex but more clinically responsive environment for stomach cancer care, where treatment value is increasingly measured by survival, functional recovery, quality of life, and continuity of care.

Cumulative Impact of Artificial Intelligence on Stomach Cancer Care

Artificial intelligence is increasingly influencing stomach cancer treatment across the care continuum, particularly in image interpretation, pathology review, treatment planning, and clinical workflow optimization. In endoscopy, AI-assisted detection tools are being studied and deployed to improve recognition of suspicious gastric lesions, support earlier diagnosis, and reduce variability between operators, especially in settings with structured screening or high endoscopy volumes. In radiology, machine learning models are being evaluated for tumor staging, treatment response assessment, lymph node evaluation, and recurrence-risk prediction using imaging features. Digital pathology and computational analysis can support evaluation of histologic patterns and biomarker expression, although clinical deployment still requires external validation, quality control, interoperability, and regulatory oversight. AI is also being applied to integrate electronic health records, molecular profiles, laboratory data, imaging results, and clinical notes to support multidisciplinary tumor board decisions. The cumulative impact is not a replacement of clinical expertise but a shift toward more data-enabled decision support, faster triage, and more consistent interpretation. Responsible implementation depends on transparent algorithms, representative training datasets, cybersecurity safeguards, clinician oversight, and evidence that AI tools improve outcomes without widening disparities.

Key Regional Insights for Stomach Cancer Treatment

Asia-Pacific carries a substantial gastric cancer burden, driven in part by high incidence in East Asian countries and established population-level screening practices in selected health systems. Japan and South Korea have long-standing gastric cancer screening programs that support earlier detection and greater use of endoscopic treatment for eligible early-stage disease, while China is expanding cancer control initiatives, endoscopy capacity, molecular diagnostics, and precision oncology capabilities across major urban centers. In North America, stomach cancer is less common than several other malignancies, but treatment is highly influenced by biomarker testing, multidisciplinary care, clinical trial participation, and access to advanced systemic therapies; the United States and Canada emphasize evidence-based guidelines, supportive oncology services, and structured referral pathways. Latin America faces uneven access to early diagnosis, surgical oncology capacity, pathology infrastructure, radiotherapy services, and newer systemic therapies, with Brazil and Mexico serving as important regional centers for oncology service development. Europe demonstrates strong adoption of guideline-based perioperative therapy, centralized cancer pathways, and molecular diagnostics, although variations remain between Western, Southern, Central, and Eastern European systems in reimbursement and specialist access. The Middle East is strengthening oncology infrastructure, particularly in Gulf countries where tertiary cancer centers, digital health programs, and precision medicine initiatives are expanding, while access can vary across lower-resource settings. Africa faces the most pronounced challenges in timely diagnosis, endoscopy availability, pathology capacity, oncology workforce, radiotherapy access, and affordability of treatment, making health system strengthening, early referral pathways, and essential cancer medicine access critical for improving stomach cancer outcomes.

Key Group Insights for Stomach Cancer Treatment

ASEAN countries present a mixed stomach cancer treatment environment, with advanced oncology centers in urban hubs and persistent gaps in rural screening, diagnostic endoscopy, pathology turnaround, and access to biomarker testing. GCC health systems are investing in tertiary cancer centers, digital health infrastructure, specialist oncology services, and national cancer strategies, supporting wider adoption of multidisciplinary stomach cancer care and advanced systemic treatment where clinically indicated. The European Union benefits from coordinated cancer policy frameworks, cross-border research collaboration, cancer registry infrastructure, and established clinical guideline adoption, though differences in reimbursement, diagnostic capacity, workforce availability, and referral pathways affect treatment consistency. BRICS countries collectively represent a broad and diverse gastric cancer care setting, with China and India managing large patient volumes, Brazil and Russia developing specialized oncology networks, and South Africa facing access constraints that reflect wider regional disparities. G7 countries generally show strong availability of advanced diagnostics, specialist surgery, immunotherapy, targeted treatment, supportive care, and clinical research infrastructure, while also facing pressures related to aging populations, treatment affordability, workforce capacity, and equitable access. NATO member countries overlap with many high-income health systems in North America and Europe, where cancer preparedness, medical supply resilience, digital coordination, and cross-institutional collaboration support continuity of complex oncology care, though national policy, reimbursement, and service organization differences continue to shape patient access.

Key Country Insights for Stomach Cancer Treatment

The United States has a highly specialized stomach cancer treatment ecosystem built around multidisciplinary oncology teams, biomarker testing, clinical trials, immunotherapy, targeted therapy, and complex surgical care for eligible patients. Canada emphasizes publicly funded cancer pathways, provincial oncology programs, and guideline-based management, though geography can affect access to specialized surgical, endoscopic, and diagnostic services. Mexico and Brazil continue to strengthen cancer care capacity, with major urban centers offering advanced oncology services while delayed diagnosis, out-of-pocket burden, and uneven access remain important barriers. The United Kingdom applies national cancer pathways and evidence-based assessment for therapy adoption, while Germany and France maintain strong specialist oncology networks, surgical expertise, diagnostic infrastructure, and molecular testing capabilities. Italy and Spain combine guideline-led perioperative treatment, surgical oncology, radiation oncology, and supportive care, with regional variations in access and service delivery. Russia has been expanding oncology modernization initiatives, but regional differences in diagnostic and treatment availability continue to influence care. China is central to global gastric cancer care due to its high disease burden, growing endoscopy network, expanding molecular diagnostics capability, and increasing clinical research activity. India faces significant variation between metropolitan oncology centers and underserved regions, making affordability, early diagnosis, pathology capacity, and specialist access key priorities. Japan and South Korea are distinguished by organized screening experience, high detection of early gastric cancer, advanced endoscopic treatment expertise, and strong surgical quality systems. Australia provides guideline-based multidisciplinary care supported by specialist cancer centers and clinical research networks, with continued attention to access for rural, remote, and Indigenous populations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated stomach cancer care models that connect gastroenterology, pathology, radiology, surgical oncology, medical oncology, radiation oncology, nutrition, rehabilitation, and palliative care from the point of diagnosis. Expanding access to validated biomarker testing is essential for appropriate use of immunotherapy and targeted therapy, particularly in advanced gastric and gastroesophageal junction cancers. Healthcare organizations should invest in endoscopy quality improvement, early referral pathways, standardized staging workups, and rapid pathology reporting to reduce delays and improve treatment selection. Decision-makers should support clinician education on evolving treatment algorithms, toxicity management, molecular interpretation, nutritional assessment, and shared decision-making. Digital infrastructure should be strengthened to enable multidisciplinary tumor boards, real-world evidence generation, treatment adherence monitoring, survivorship planning, and patient navigation. For emerging and resource-constrained settings, practical priorities include increasing endoscopy availability, improving pathology turnaround times, strengthening surgical oncology training, expanding radiotherapy access, and building affordable access pathways for essential systemic therapies. Across all settings, leaders should measure care quality through evidence-based indicators such as time to diagnosis, completeness of staging, biomarker testing rates, treatment completion, postoperative outcomes, symptom control, nutritional status, and patient-reported quality of life.

Research Methodology

This executive summary is developed through a secondary research approach using verified clinical, regulatory, epidemiological, and public health sources. The methodology emphasizes evidence from peer-reviewed medical literature, oncology treatment guidelines, cancer registry publications, public health agency materials, regulatory documents, and consensus recommendations from recognized clinical organizations. Insights are synthesized qualitatively to assess treatment evolution, technology adoption, regional access patterns, and clinical practice implications without using market sizing, market share, or forecasting. Regional, group, and country perspectives are evaluated through the lens of disease burden, screening practices, diagnostic capacity, treatment infrastructure, biomarker testing availability, reimbursement environments, oncology workforce readiness, and health system preparedness. The analysis prioritizes reproducibility, source credibility, clinical relevance, and alignment with current standards of care. Because stomach cancer treatment is rapidly evolving, the interpretation focuses on durable evidence-backed themes such as biomarker-guided therapy, multidisciplinary care, early detection, supportive oncology, and equitable access rather than speculative commercial projections.

Conclusion

Stomach cancer treatment is advancing toward precision, integration, and earlier intervention. Surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, endoscopic procedures, nutritional care, and palliative support are increasingly coordinated through multidisciplinary pathways that reflect tumor stage, molecular profile, patient condition, and health system capacity. Artificial intelligence, molecular diagnostics, and digital care coordination are strengthening the ability to detect disease, personalize therapy, and monitor outcomes, but their value depends on equitable implementation and validated clinical benefit. Regional differences remain substantial, with East Asian screening experience, high-income country access to advanced therapies, and infrastructure gaps in many low- and middle-resource settings shaping treatment realities. The most effective strategies will be those that improve diagnostic accuracy, expand biomarker access, reduce treatment delays, support evidence-based therapy sequencing, strengthen supportive care, and place patient quality of life at the center of care. As scientific evidence continues to mature, the stomach cancer treatment landscape will reward stakeholders that combine innovation with affordability, operational readiness, and measurable clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Stomach Cancer Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
    • 7.2.1. Fluoropyrimidine-Based
    • 7.2.2. Platinum-Based
    • 7.2.3. Taxane-Based
  • 7.3. Immunotherapy
  • 7.4. Radiotherapy
    • 7.4.1. Brachytherapy
    • 7.4.2. External Beam
  • 7.5. Surgery
    • 7.5.1. Partial Gastrectomy
    • 7.5.2. Total Gastrectomy
  • 7.6. Targeted Therapy
  • 7.7. Supportive & Adjunctive Therapy

8. Stomach Cancer Treatment Market, by Product Type

  • 8.1. Introduction
  • 8.2. Drugs
    • 8.2.1. Cytotoxic Chemotherapy Drugs
      • 8.2.1.1. Fluoropyrimidines
      • 8.2.1.2. Taxanes
      • 8.2.1.3. Cisplatin
    • 8.2.2. Biologics & Monoclonal Antibodies
    • 8.2.3. Antibody-Drug Conjugates
  • 8.3. Medical Device & Equipment
    • 8.3.1. Surgical Products
    • 8.3.2. Endoscopes
    • 8.3.3. Radiation Devices
    • 8.3.4. Pumps & Catheters

9. Stomach Cancer Treatment Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral

10. Stomach Cancer Treatment Market, by Stage

  • 10.1. Introduction
  • 10.2. Stage I
  • 10.3. Stage II
  • 10.4. Stage III
  • 10.5. Stage IV

11. Stomach Cancer Treatment Market, by Indication

  • 11.1. Introduction
  • 11.2. Gastric Adenocarcinoma
  • 11.3. Gastric Lymphoma
  • 11.4. Gastroesophageal Junction Adenocarcinoma
  • 11.5. Gastric Neuroendocrine Tumors

12. Stomach Cancer Treatment Market, by End User

  • 12.1. Introduction
  • 12.2. Homecare
  • 12.3. Hospitals
  • 12.4. Specialty Clinics
  • 12.5. Radiation Oncology Centers

13. Stomach Cancer Treatment Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacy
  • 13.3. Online Pharmacy
  • 13.4. Retail Pharmacy

14. Stomach Cancer Treatment Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Stomach Cancer Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Stomach Cancer Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Amgen Inc.
  • 18.2. Astellas Pharma Inc.
  • 18.3. AstraZeneca PLC
  • 18.4. Bayer AG
  • 18.5. BeOne Medicines, Ltd.
  • 18.6. Boehringer Ingelheim International GmbH
  • 18.7. Bristol Myers Squibb Company
  • 18.8. Cipla Limited
  • 18.9. Daiichi Sankyo Company, Limited
  • 18.10. Eisai Co., Ltd.
  • 18.11. Eli Lilly and Company
  • 18.12. F. Hoffmann-La Roche Ltd.
  • 18.13. Gilead Sciences, Inc.
  • 18.14. GlaxoSmithKline PLC
  • 18.15. Incyte Corporation
  • 18.16. Ipsen Pharma
  • 18.17. Johnson & Johnson Services Inc.
  • 18.18. LES LABORATOIRES SERVIER
  • 18.19. Merck & Co., Inc.
  • 18.20. Novartis AG
  • 18.21. Ono Pharmaceutical
  • 18.22. Otsuka Pharmaceutical Co., Ltd.
  • 18.23. Pfizer Inc.
  • 18.24. Prestige Biopharma
  • 18.25. Sanofi S.A.
  • 18.26. Sumitomo Pharma Co., Ltd.
  • 18.27. Sun Pharmaceuticals Limited
  • 18.28. Taiho Pharmaceutical Co., Ltd.
  • 18.29. Takeda Pharmaceutical Company Limited
  • 18.30. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL STOMACH CANCER TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL STOMACH CANCER TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL STOMACH CANCER TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL STOMACH CANCER TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL STOMACH CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FLUOROPYRIMIDINE-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FLUOROPYRIMIDINE-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FLUOROPYRIMIDINE-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLATINUM-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLATINUM-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PLATINUM-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TAXANE-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TAXANE-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TAXANE-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EXTERNAL BEAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EXTERNAL BEAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EXTERNAL BEAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PARTIAL GASTRECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PARTIAL GASTRECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PARTIAL GASTRECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TOTAL GASTRECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TOTAL GASTRECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TOTAL GASTRECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUPPORTIVE & ADJUNCTIVE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUPPORTIVE & ADJUNCTIVE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUPPORTIVE & ADJUNCTIVE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYTOTOXIC CHEMOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYTOTOXIC CHEMOTHERAPY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYTOTOXIC CHEMOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FLUOROPYRIMIDINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FLUOROPYRIMIDINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FLUOROPYRIMIDINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TAXANES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TAXANES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TAXANES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CISPLATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CISPLATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CISPLATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS & MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS & MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS & MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MEDICAL DEVICE & EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MEDICAL DEVICE & EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MEDICAL DEVICE & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SURGICAL PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SURGICAL PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SURGICAL PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOSCOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENDOSCOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOSCOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RADIATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RADIATION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RADIATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PUMPS & CATHETERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PUMPS & CATHETERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PUMPS & CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL STAGE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL STAGE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL STAGE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL STAGE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL STAGE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL STAGE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL STAGE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL STAGE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL STAGE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL STAGE IV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL STAGE IV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL STAGE IV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTRIC ADENOCARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GASTRIC ADENOCARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTRIC ADENOCARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GASTRIC LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTRIC LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GASTRIC LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GASTRIC NEUROENDOCRINE TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTRIC NEUROENDOCRINE TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GASTRIC NEUROENDOCRINE TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RADIATION ONCOLOGY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RADIATION ONCOLOGY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RADIATION ONCOLOGY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 241. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 245. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 283. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 287. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 289. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 297. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 299. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 300. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 301. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 306. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 324. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 325. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 335. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 338. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 339. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 340. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 342. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 343. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY MEDICAL DEVICE & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 344. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 345. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 346. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 347. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 348. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 349. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 350. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (U